Skip to main content

Animations

MJFF Publications

1651 - 1660 of 7877 Results
Title
Year
  • Year
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • RESTRICTED
    Title: Quantitative determination of LY‐404,039, a metabotropic glutamate 2/3 receptor agonist, in rat plasma using chemical derivatization and HPLC–MRM/MS
    Journal Name: Biomedical Chromatography
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1002/bmc.5423
    Best OA location URL:
    Citation Count: 2
  • RESTRICTED
    Title: Closing the loop for patients with Parkinson disease: where are we?
    Journal Name: Nature Reviews Neurology
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1038/s41582-022-00674-1
    Best OA location URL:
    Citation Count: 19
  • RESTRICTED
    Title: Incidence of amyotrophic lateral sclerosis in older adults
    Journal Name: Muscle & Nerve
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1002/mus.27652
    Best OA location URL:
    Citation Count: 8
  • OPEN
    Title: Lipase regulation of cellular fatty acid homeostasis as a Parkinson’s disease therapeutic strategy
    Journal Name: npj Parkinson's Disease
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1038/s41531-022-00335-6
    Citation Count: 9
  • OPEN
    Title: WHOPPA Enables Parallel Assessment of Leucine-Rich Repeat Kinase 2 and Glucocerebrosidase Enzymatic Activity in Parkinson’s Disease Monocytes
    Journal Name: Frontiers in Cellular Neuroscience
    Publisher: Frontiers Media SA
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.3389/fncel.2022.892899
    Citation Count: 15
  • RESTRICTED
    Title: A step forward for LRRK2 inhibitors in Parkinson’s disease
    Journal Name: Science Translational Medicine
    Publisher: American Association for the Advancement of Science (AAAS)
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1126/scitranslmed.abq7374
    Citation Count: 9
  • OPEN
    Title: Distinct profiles of LRRK2 activation and Rab GTPase phosphorylation in clinical samples from different PD cohorts
    Journal Name: npj Parkinson's Disease
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1038/s41531-022-00336-5
    Citation Count: 16
  • RESTRICTED
    Title: Neurodegeneration and Neuroinflammation in Parkinson’s Disease: a Self-Sustained Loop
    Journal Name: Current Neurology and Neuroscience Reports
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by
    DOI - Digital Object Identifier: 10.1007/s11910-022-01207-5
    Citation Count: 23
  • RESTRICTED
    Title: Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson’s disease
    Journal Name: Science Translational Medicine
    Publisher: American Association for the Advancement of Science (AAAS)
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1126/scitranslmed.abj2658
    Best OA location URL:
    Citation Count: 136
  • OPEN
    Title: Structure of the second phosphoubiquitin–binding site in parkin
    Journal Name: Journal of Biological Chemistry
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.jbc.2022.102114
    Citation Count: 17
Filters
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.